Patent application number | Description | Published |
20080317853 | Mouth Dissolving Pharmaceutical Composition and Process for Preparing the Same - Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time. | 12-25-2008 |
20090022795 | Stable Pharmaceutical Formulation of an Acid Labile Compound and Process for Preparing the Same - The disclosed invention provides oral pharmaceutical formulations of an acid labile benzimidazole derivative comprising (a) a core comprising an acid labile benzimidazole derivative, (b) a seal coating layer, and (c) an enteric coating layer, wherein the core of the composition is devoid of any disintegrant. | 01-22-2009 |
20090175934 | Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same - Disclosed herein is an extended release pharmaceutical formulation suitable for once daily administration, comprising a highly water soluble core consisting essentially of about 30 to about 40% by weight of venlafaxine hydrochloride, about 50 to about 80% by weight of water soluble diluent and about 2 to about 10% of water soluble binder and a coating layer having an effective combination of rate controlling polymers comprising water-soluble polymer and water insoluble, water permeable polymer. | 07-09-2009 |
20090269393 | Chewable Bilayer Tablet Formulation - Disclosed herein is a tablet formulation of an objectionable tasting drug cetirizine or its pharmaceutically acceptable salt in a form of chewable bilayer tablet, wherein the formulation comprises said cetirizine, a combination of water-insoluble and water-soluble polymer in a ratio of about 1:0.5 to about 1:5 and a low molecular weight polyol, wherein the molar ratio of the low molecular weight polyol to cetirizine is more than 10, and the inactive formulation layer comprises beta-cyclodextrin and other pharmaceutically acceptable excipients. Further, the present invention provides a process for preparing the formulation. | 10-29-2009 |
20100008987 | Modified Release Pharmaceutical Composition of Bupropion Hydrochloride - A delayed extended release pharmaceutical composition includes a compressed core containing an effective amount of bupropion or its pharmaceutically acceptable salt, a water-attractant polymer. The core is preferably devoid of a stabilizer. The core is surrounded by an extended release layer, which is free of plasticizer and pore-forming agent. The extended release layer is surrounded by a delayed release layer. Alternating coats of extended release layer and delayed release layer may follow. A preferred extended release layer includes ethylcellulose and hydroxypropyl cellulose or hydroxypropyl methylcellulose and a preferred delayed release layer includes methacrylic acid copolymer and hydroxypropyl methylcellulose phthalate, lactose and a combination of triethyl citrate and polyethylene glycol and talc. A method of preparing the delayed extended release bupropion hydrochloride containing pharmaceutical composition is also disclosed. | 01-14-2010 |
20100016322 | Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same - Water dispersible compressed tablets and a process for preparing the same. The tablet comprising about 0.1 to 50% w/w of lamotrigine or its pharmaceutically acceptable salts, solvates, hydrates or polymorphs, about 5 to about 50% w/w of a water-soluble diluent(s), about 15 to about 70% w/w of a water swellable diluent(s), optionally one or more pharmaceutically acceptable adjuvants, wherein the ratio of water-soluble diluent(s) to water swellable diluents(s) is from about 0.6 to about 0.9 and said composition is essentially free of disintegrant, superdisintegrant and swellable clay. | 01-21-2010 |
20100226979 | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate - Disclosed herein a taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insoluble polymer, wherein said active is first blended with an adsorbent such as magnesium aluminium silicate to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insoluble polymer to strengthen the taste masking without affecting the release of said active. | 09-09-2010 |
20100291225 | Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same - Disclosed herein is a stabilized sustained release pharmaceutical composition of bupropion hydrochloride and process for preparing the same, wherein said pharmaceutical composition comprising therapeutically effective amount of uncoated fine bupropion hydrochloride and pharmaceutically acceptable adjuvants, and wherein the composition is free of an acidic stabilizer and contains less than about 0.3% by weight of m-chlorobenzoic acid. | 11-18-2010 |
20110177164 | Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof - A stabilized pharmaceutical composition of benzimidazole compounds preferably amorphous form of esomeprazole and a process for preparing the same. The pharmaceutical compositions formulated into solid dosage forms preferably multiple unit tablet dosage forms and capsules and a method for preparing the same. | 07-21-2011 |
20110189274 | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates - A stable pharmaceutical composition includes a therapeutically effective amount of montelukast or its pharmaceutically acceptable salts, solvates or hydrates and a blend which includes microcrystalline cellulose and a flavoring agent and wherein said composition is substantially free of montelukast sulfoxide degradation product. A process for preparing such composition is also disclosed. | 08-04-2011 |